Warning! GuruFocus detected
4 Severe warning signs
with 1T3.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Syndax Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US87164F1057
Description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.69 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 1.2 | |||||
| Debt-to-EBITDA | -1.1 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.37 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -52.6 | |||||
| 3-Year Book Growth Rate | -23.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.35 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 142.41 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.46 | |||||
| 9-Day RSI | 42.34 | |||||
| 14-Day RSI | 42.48 | |||||
| 3-1 Month Momentum % | 19.51 | |||||
| 6-1 Month Momentum % | -12.5 | |||||
| 12-1 Month Momentum % | -25.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.82 | |||||
| Quick Ratio | 5.82 | |||||
| Cash Ratio | 5.63 | |||||
| Days Inventory | 161.73 | |||||
| Days Sales Outstanding | 117.18 | |||||
| Days Payable | 5569.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.9 | |||||
| Shareholder Yield % | -7.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.51 | |||||
| Operating Margin % | -1434.43 | |||||
| Net Margin % | -1346.11 | |||||
| FCF Margin % | -1164.26 | |||||
| ROE % | -74.65 | |||||
| ROA % | -57.26 | |||||
| ROIC % | -478.97 | |||||
| 3-Year ROIIC % | -257.22 | |||||
| ROC (Joel Greenblatt) % | -24055.57 | |||||
| ROCE % | -63.55 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 47.75 | |||||
| PB Ratio | 3.92 | |||||
| Price-to-Tangible-Book | 3.92 | |||||
| EV-to-EBIT | -2.96 | |||||
| EV-to-Forward-EBIT | -3.63 | |||||
| EV-to-EBITDA | -2.96 | |||||
| EV-to-Forward-EBITDA | -3.63 | |||||
| EV-to-Revenue | 39.24 | |||||
| EV-to-Forward-Revenue | 7.52 | |||||
| EV-to-FCF | -3.38 | |||||
| Price-to-Net-Current-Asset-Value | 6.78 | |||||
| Price-to-Net-Cash | 7.72 | |||||
| Earnings Yield (Greenblatt) % | -33.78 | |||||
| FCF Yield % | -24.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Syndax Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 21.849 | ||
| EPS (TTM) (€) | -3.459 | ||
| Beta | 0.66 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 36.35 | ||
| 14-Day RSI | 42.48 | ||
| 14-Day ATR (€) | 0.396993 | ||
| 20-Day SMA (€) | 12.785 | ||
| 12-1 Month Momentum % | -25.76 | ||
| 52-Week Range (€) | 11.4 - 22.8 | ||
| Shares Outstanding (Mil) | 86.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Syndax Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Syndax Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Syndax Pharmaceuticals Inc Frequently Asked Questions
What is Syndax Pharmaceuticals Inc(STU:1T3)'s stock price today?
The current price of STU:1T3 is €12.20. The 52 week high of STU:1T3 is €22.80 and 52 week low is €11.40.
When is next earnings date of Syndax Pharmaceuticals Inc(STU:1T3)?
The next earnings date of Syndax Pharmaceuticals Inc(STU:1T3) is 2025-05-08 Est..
Does Syndax Pharmaceuticals Inc(STU:1T3) pay dividends? If so, how much?
Syndax Pharmaceuticals Inc(STU:1T3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers